ArticleInternational journal of Alzheimer's disease2012
Tau and caspase 3 as targets for neuroprotection.
Article in International journal of Alzheimer's disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Review
- Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging.Aging and disease · 2022Review
- Distinct Impairments Characterizing Different ADNP Mutants Reveal Aberrant Cytoplasmic-Nuclear Crosstalk.Cells · 2022Article
- STOP Codon Mutations at Sites of Natural Caspase Cleavage Are Implicated in Autism and Alzheimer's Disease: The Case of ADNP.Frontiers in endocrinology · 2022Article
- Proteome profiling of different rat brain regions reveals the modulatory effect of prolonged maternal separation on proteins involved in cell death-related processes.Biological research · 2021Article
- Neuroprotective Effect of Astragaloside IV on Cerebral Ischemia/Reperfusion Injury Rats Through Sirt1/Mapt Pathway.Frontiers in pharmacology · 2021Article
- Immune-modulatory Properties of the Octapeptide NAP inMicroorganisms · 2020Article
- Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.Journal of food and drug analysis · 2019Article
- The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.Translational psychiatry · 2019Article
- Dihydrolipoamide dehydrogenase suppression induces human tau phosphorylation by increasing whole body glucose levels in a C. elegans model of Alzheimer's Disease.Experimental brain research · 2018Article
- Tau Diagnostics and Clinical Studies.Journal of molecular neuroscience : MN · 2017Article
- Intranasal Delivery of Recombinant NT4-NAP/AAV Exerts Potential Antidepressant Effect.Neurochemical research · 2016Article
- Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.Journal of molecular neuroscience : MN · 2016Review
- Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice.European journal of microbiology & immunology · 2015Article
- Impairment of Rat Spatial Learning and Memory in a New Model of Cold Water-Induced Chronic Hypothermia: Implication for Alzheimer's Disease.Neurotoxicity research · 2015Article
- Autophagy has a key role in the pathophysiology of schizophrenia.Molecular psychiatry · 2015Article
- ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.Frontiers in aging neuroscience · 2015Review
- Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.Journal of molecular neuroscience : MN · 2014Article
- Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death.Journal of molecular neuroscience : MN · 2014Article
- NAP alpha-aminoisobutyric acid (IsoNAP).Journal of molecular neuroscience : MN · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The peptide drug candidate NAP (davunetide) has demonstrated protective effects in various in vivo and in vitro models of neurodegeneration. NAP was shown to reduce tau hyperphosphorylation as well as to prevent caspase-3 activation and cytochrome-3 release from mitochondria, both characteristic of apoptotic cell death. Recent studies suggest that caspases may play a role in tau pathology. The purpose of this study was to evaluate the effect of NAP on tau hyperphosphorylation and caspase activity in the same biological system. Our experimental setup used primary neuronal cultures subjected to oxygen-glucose deprivation (OGD), with and without NAP or caspase inhibitor. Cell viability was assessed by measuring mitochondrial activity (MTS assay), and immunoblots were used for analyzing protein level. It was shown that apoptosis was responsible for all cell death occurring following ischemia, and NAP treatment showed a concentration-dependent protection from cell death. Ischemia caused an increase in the levels of active caspase-3 and hyperphosphorylated tau, both of which were prevented by either NAP or caspase-inhibitor treatment. Our data suggest that, in this model system, caspase activation may be an upstream event to tau hyperphosphorylation, although additional studies will be required to fully elucidate the cascade of events.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.